- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Authors
Keywords
Chronic myeloid leukemia, Molecular mechanism, Tyrosine kinase inhibitor, Resistance mutations
Journal
Current Hematologic Malignancy Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-28
DOI
10.1007/s11899-019-00543-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2018) Jerald P. Radich et al. Journal of the National Comprehensive Cancer Network
- Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
- (2017) Ami B. Patel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
- (2016) Simona Soverini et al. Oncotarget
- New Methodologies in the Molecular Monitoring of CML
- (2016) Cecilia C. S. Yeung et al. Current Hematologic Malignancy Reports
- Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
- (2015) Andreas Hochhaus et al. ANNALS OF HEMATOLOGY
- Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review
- (2015) Ke Yang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
- (2015) T P Hughes et al. LEUKEMIA
- Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
- (2015) L Lu et al. LEUKEMIA
- Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors
- (2015) Christopher A. Eide et al. Current Hematologic Malignancy Reports
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Structure, Function, and Resistance in Chronic Myeloid Leukemia
- (2014) Jerald Radich CANCER CELL
- Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
- (2014) Katerina Machova Polakova et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
- (2014) A M Eiring et al. LEUKEMIA
- The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia
- (2014) A Giannoudis et al. LEUKEMIA
- A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
- (2014) L. Ma et al. Science Translational Medicine
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
- (2013) C. C. Smith et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
- (2013) S. Soverini et al. BLOOD
- Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
- (2013) S. Branford et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
- (2013) L N Eadie et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- Mechanisms of resistance to BCR-ABL and other kinase inhibitors
- (2012) Allan Joaquim Lamontanara et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
- (2011) A. R. Ibrahim et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Chronic myeloid leukemia: mechanisms of blastic transformation
- (2010) Danilo Perrotti et al. JOURNAL OF CLINICAL INVESTIGATION
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
- (2010) Xin An et al. LEUKEMIA RESEARCH
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
- (2009) D. Milojkovic et al. CLINICAL CANCER RESEARCH
- Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
- (2009) T. D. Kim et al. HAEMATOLOGICA
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib
- (2008) Navratna Vajpai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now